Grassley Rx Import Bill Offers R&D Tax Incentive To Cooperating Manufacturers
This article was originally published in The Pink Sheet Daily
Executive Summary
The "REMEDIES Act" would increase the research tax credit by 20% to companies that certify they have not directly or indirectly moved to prevent authorized importation. The program is limited to Canada for the first two years; in the third year it expands to include Europe, Japan, Australia and New Zealand.
You may also be interested in...
Health Committee Hearings To Focus On HHS Importation Report
The committee will also hold hearings on the Dorgan/Snowe importation bill by the end of April. The legislation, which differs from legislation introduced by the senators last year, is backed by Finance Committee Chairman Grassley.
Health Committee Hearings To Focus On HHS Importation Report
The committee will also hold hearings on the Dorgan/Snowe importation bill by the end of April. The legislation, which differs from legislation introduced by the senators last year, is backed by Finance Committee Chairman Grassley.
Sen. Grassley Will Push For Passage Of Rx Importation Bill This Year
The Finance Committee chairman says an importation bill may result in less money for research in the U.S., but would be offset by higher drug prices in other countries.